Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Anti-CD19 CAR-T cells |
Trade Name | |
Synonyms | |
Drug Descriptions |
Anti-CD19 CAR-T cells are T-cells that express a chimeric antigen receptor that targets the CD19 surface protein on B-lymphocytes, which results in anti-tumor activity in B-cell malignancies (PMID: 25999455, PMID: 26425336). |
DrugClasses | CD19 Immune Cell Therapy 62 |
CAS Registry Number | NA |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
ABT-737 + Anti-CD19 CAR-T cells | ABT-737 Anti-CD19 CAR-T cells | 0 | 0 |
Anti-CD19 CAR-T cells | Anti-CD19 CAR-T cells | 1 | 8 |
Anti-CD19 CAR-T cells + Cyclophosphamide + Fludarabine | Anti-CD19 CAR-T cells Cyclophosphamide Fludarabine | 0 | 1 |
Anti-CD19 CAR-T cells + Cyclophosphamide + Fludarabine + Rituximab | Anti-CD19 CAR-T cells Cyclophosphamide Fludarabine Rituximab | 0 | 1 |